Voyager Therapeutics Expands Alzheimer's Disease Pipeline with Novel APOE Gene Therapy Program

Voyager Therapeutics announced a new wholly-owned Alzheimer's disease (AD) program targeting apolipoprotein E (APOE), a major genetic risk factor for ...

Voyager Therapeutics Expands Alzheimer's Disease Pipeline with Novel APOE Gene Therapy Program

Amgen's Repatha Phase 3 VESALIUS-CV Trial Data to be Presented at AHA 2025

Genentech's Gazyva Shows Positive Phase III Data with Significant Reduction in Disease Activity for Systemic Lupus Erythematosus

GeneSight Test Shows Faster Remission and Response in Depression Treatment: Post-Hoc Analysis

Foghorn Therapeutics Announces Updates for Selective ARID1B, CBP, and EP300 Degrader Programs

Wave Life Sciences Announces Positive Target Engagement Data from INLIGHT Clinical Trial of WVE-007 for Obesity

Anaptys Announces Positive Phase 2b Results for Rosnilimab in Rheumatoid Arthritis

AbbVie Announces Positive Phase 3 Results for Upadacitinib (RINVOQ®) in Vitiligo

TG Therapeutics Completes Enrollment in Phase 3 ENHANCE Trial of Simplified Dosing for BRIUMVI in Multiple Sclerosis

Kyverna Therapeutics Announces Positive Phase 2 Interim Data for KYV-101 in Generalized Myasthenia Gravis

Sionna Therapeutics Announces Phase 1 Data for SION-719 and SION-451 and Preclinical Data on NBD1 Stabilizers in Cystic Fibrosis

Daewoong Pharmaceutical's Bersiporocin Receives Positive IDMC Safety Review in Phase 2 IPF Trial

Innovent's Mazdutide Demonstrates Superior Glycemic Control and Weight Loss Compared to Semaglutide in Phase 3 DREAMS-3 Trial

Xencor Presents Phase 1 Data for XmAb819 in Clear Cell Renal Cell Carcinoma

Cullinan Therapeutics Presents Preclinical Data for CLN-978 Supporting Clinical Development in Autoimmune Diseases at ACR Convergence 2025

Lilly's Omvoh (mirikizumab-mrkz) Shows Improvement in Bowel Urgency for Ulcerative Colitis Patients

Moderna's Phase 3 CMV Vaccine Trial Fails to Meet Primary Efficacy Endpoint

Kyverna Therapeutics Announces Conference Call on Interim Phase 2 Data of KYV-101 in Generalized Myasthenia Gravis

Rozanolixizumab Prevents Congenital Heart Block Recurrence in High-Risk Pregnancy

OS Therapies Announces Positive Survival Data for OST-HER2 in Metastatic Osteosarcoma Subgroups

AskBio Announces Positive 12-Month Data from Phase 1 Trial of AB-1002 Gene Therapy for Congestive Heart Failure in Nature Medicine

IDEAYA Biosciences Announces Positive Phase 2 Data for Darovasertib in Neoadjuvant Primary Uveal Melanoma

Sionna Therapeutics Initiates Phase 2a Trial of SION-719 for Cystic Fibrosis

Apnimed Presents Phase 3 Data for AD109 in Obstructive Sleep Apnea at CHEST 2025

CatalYm Presents Positive Long-Term Phase 1/2a Data for Visugromab in CPI-Refractory Tumors at ESMO 2025

Olema Oncology Announces Positive Phase 1b/2 Data of Palazestrant Plus Ribociclib in ER+/HER2- Metastatic Breast Cancer at ESMO 2025

Disc Medicine to Present Phase 1b Data of DISC-0974 in CKD Patients with Anemia at ASN Kidney Week 2025

SystImmune and Bristol Myers Squibb Announce Phase I Results of Iza-bren (EGFR x HER3 ADC) in Advanced Solid Tumors

Exelixis Announces Positive Phase 3 Results for Zanzalintinib and Atezolizumab Combination in Metastatic Colorectal Cancer

AlphaMedix Phase 2 Data Shows Potential in Gastroenteropancreatic Neuroendocrine Tumors

AB Science Announces Initial Phase 1 Data for AB8939 and Venetoclax Combination in Refractory or Relapsed Acute Myeloid Leukemia

Praxis Announces Positive Phase 3 Results for Ulixacaltamide in Essential Tremor

Vor Bio Announces Positive Phase 3 Results of Telitacicept in Systemic Lupus Erythematosus Published in NEJM

Nuvectis Pharma Announces Upcoming Presentations for NXP900 at AACR-NCI-EORTC Conference

Aicuris' Pritelivir Meets Primary Endpoint in Phase 3 Trial for Refractory Herpes Simplex Virus in Immunocompromised Patients

Spago Nanomedical Announces Positive Data and Dose Increase Recommendation for 177Lu-SN201 in Phase I/IIa Tumorad-01 Study

Gilead and Kite Present New Cancer Data at ESMO 2025, Highlighting Trodelvy's Potential in Metastatic TNBC

Boehringer and Click Therapeutics present positive Phase III data for CT-155 in Schizophrenia

Encoded Therapeutics Announces Positive Preclinical Data for Non-Opioid Gene Therapy Candidate for Chronic Pain

Taysha Gene Therapies Presents New Data on TSHA-102 for Rett Syndrome at CNS Annual Meeting

GlyTR Therapeutics Announces Publication of Pan-Cancer Immunotherapy Platform Study in Cell

BrYet US Receives Approval to Initiate Phase 1/2 Trial of ML-016 in Advanced Cancers with Lung and/or Liver Involvement in Australia

Prilenia and Ferrer Announce Phase 3 ALS Study of Pridopidine at NEALS 2025

Editas Medicine Announces EDIT-401 Oral Presentation at ESGCT Congress and Participation in Investor Conferences

Myrtelle Announces Encouraging Interim Results from Phase 1/2 Gene Therapy Trial for Canavan Disease

Candel Therapeutics to Present CAN-2409 Data at SITC 2025

Invivyd Announces U.S. IND Clearance and FDA Alignment for VYD2311 COVID Prevention Program

DATROWAY® Improves Overall and Progression-Free Survival in Metastatic Triple-Negative Breast Cancer

Marker Therapeutics Announces First Patient Treated in Off-the-Shelf Program for AML and MDS

Abivax Announces Positive Results from ABTECT Induction Trials of Obefazimod in Ulcerative Colitis Patients

Bolt Biotherapeutics Updates on BDC-4182 and Extends Cash Runway into 2027

EG 427 Announces Positive Topline Results for EG110A in Neurogenic Bladder Patients

Lisata Therapeutics Announces Positive Preliminary Results from CENDIFOX Trial in Pancreatic Cancer

CeleCor Therapeutics Announces Positive Phase 3 Results for Disaggpro in Heart Attack Patients

OS Therapies to Present at BioFuture 2025 and Discuss OST-HER2 Clinical Development

ONWARD Medical Announces Positive Results for ARC-IM Therapy in Blood Pressure Regulation after Spinal Cord Injury

Skyhawk Therapeutics Announces Positive Interim Phase 1 Results for SKY-0515 in Huntington's Disease

Palvella Therapeutics Announces Publication on Rapamycin for Venous Malformations

Protagonist Announces Clinical Data Presentations for Icotrokinra and PN-881 at EADV 2025 Congress

Atossa Therapeutics Seeks Accelerated Approval for Low-Dose (Z)-Endoxifen for Breast Cancer Risk Reduction

CASI Pharmaceuticals Announces Dose Escalation in Phase 1 CID-103 ITP Study

Alto Neuroscience Validates EEG Biomarker for Schizophrenia, Strengthening Phase 2 Trial of ALTO-101

Positive Phase 1/2 Data for IDE397 and Trodelvy Combination in MTAP-Deletion Urothelial Cancer

Positive Phase 1 Data for IDE849 (SHR-4849) in Small Cell Lung Cancer

Oncolytics Biotech Highlights Pelareorep Efficacy in Metastatic Colorectal Cancer

RYBREVANT® and LAZCLUZE® Combination Prevents Acquired Resistance in First-Line EGFR-Mutated NSCLC

iMDx Enrolls First Patient in GraftAssureDx Clinical Trial

Regeneron's Positive Phase 3 Allergy Trials Advance First-in-Class Antibody Blockers

Rapport Therapeutics to Announce Topline Phase 2a Results for RAP-219 in Focal Onset Seizures

SCYNEXIS Presents Data on Second-Generation Antifungal SCY-247 at TIMM-12

Valitor Presents Preclinical Data on VLTR-559 for Wet AMD

Gain Therapeutics Receives Approval for Phase 1b Dosing Extension of GT-02287 for Parkinson's Disease

Clene Presents Preclinical Data Supporting CNM-Au8 for Parkinson's Disease

AL-S Pharma Announces Positive Phase 2 Results for AP-101 in ALS Treatment

Sanofi's Amlitelimab Shows Promise in Phase 3 Atopic Dermatitis Study

Aspire Biopharma Announces Positive Final Results for Sublingual Aspirin in Treating Heart Attacks

Personalis' NeXT Personal MRD Test Shows Superiority in Neoadjuvant Lung Cancer Trial

Zymeworks Discontinues ZW171 Clinical Development

Compass Pathways Announces Positive Phase 2 Results for COMP360 Psilocybin in PTSD

Ascletis to Present ASC30 Data at EASD Annual Meeting